Table 2.

Whole brain V_T, BP_ND, K₁/k₂, K₁, and k₂ of [¹¹C]flumazenil before and after tariquidar administration derived using the 1TC model and SRTM.

	VT			BPND			K1/k2			K1			k2
Patient	Baseline	Post TQD	Change (%)a	Baseline	Post TQD	Change (%)a	Baseline	Post TQD	Change (%)a	Baseline	Post TQD	Change (%)a	Baseline	Post TQD	Change (%)a
1	6.47	6.02	−7	7.28	4.21	−42	0.78	1.16	48	0.39	0.41	5	0.50	0.36	−29
2	4.84	5.57	15	4.48	3.91	−13	0.88	1.13	28	0.26	0.27	2	0.30	0.24	−20
3	4.43	5.06	14	4.17	3.90	−6	0.86	1.03	21	0.33	0.38	13	0.39	0.36	−7
4	4.66	5.15	10	4.30	3.97	−8	0.88	1.03	18	0.28	0.31	11	0.32	0.30	−5
5	4.90	5.42	11	4.88	4.13	−15	0.83	1.06	27	0.33	0.33	−1	0.40	0.31	−22
6	5.59	5.72	2	5.28	3.33	−37	0.89	1.32	48	0.37	0.35	−7	0.42	0.26	−37
7	4.87	5.60	15	4.38	4.78	9	0.91	0.97	7	0.26	0.27	7	0.28	0.28	0
8	6.12	7.05	15	3.86	4.65	20	1.26	1.25	−1	0.38	0.37	−3	0.30	0.29	−2
9	4.84	5.33	10	3.51	3.32	−5	1.07	1.23	15	0.29	0.29	−1	0.27	0.23	−14
AVG	5.19	5.66	10	4.68	4.02	−11	0.93	1.13	23	0.32	0.33	3	0.35	0.29	−15
SD	0.70	0.60	7	1.10	0.50	20	0.15	0.12	17	0.05	0.05	6	0.08	0.05	13

V_T: distribution volume (1TC model); BP_ND: binding potential (SRTM model); K₁/k₂: ratio of rate constants of [¹¹C]flumazenil transport across the blood–brain barrier (both 1TC model and SRTM); K₁: influx rate constant (mL · cm⁻³ · min⁻¹) (1TC model); k₂: efflux rate constant (min⁻¹) (both 1TC model and SRTM); 1TC model: 1 tissue compartment model; SRTM: simplified reference tissue model; TQD: tariquidar; AVG: average; SD: standard deviation.

^aPercentage change after tariquidar administration relative to baseline.